Helps bring Parkinson’s
patients together with
the activities they love
• Clinical evidence supports AZILECT® (rasagiline tablets) use throughout Parkinson’s
disease (PD) 1
— 3 Class I studies with more than 1500 patients1
• Improves PD symptoms and helps maintain activities of daily living (ADLs) in
• Reduces “o;” time by nearly 2 hours in levodopa-treated patients1
• Generally well tolerated1
• Convenient, once-daily dosing1
AZILECT is indicated for the treatment of the signs and symptoms of idiopathic Parkinson’s disease (PD)
as initial monotherapy and as adjunct therapy to levodopa.
IMPORTANT SAFETY INFORMATION
• AZILECT is contraindicated with meperidine; the analgesics tramadol, methadone, and propoxyphene;
the antitussive agent dextromethorphan; as well as St. John’s wort and cyclobenzaprine. AZILECT is
also contraindicated with other MAOIs.
• In general, the combination of AZILECT and antidepressants should be avoided. Caution should be used
when giving AZILECT concurrently with CYP1A2 inhibitors such as ciprofloxacin. Patients with moderate
to severe hepatic impairment should not take AZILECT. The daily dose of AZILECT should not exceed 1 mg
because of the risks associated with nonselective inhibition of MAO. PD patients are advised to monitor for
melanoma frequently and see a dermatologist on a regular basis.
• The most common side e;ects as monotherapy include: flu syndrome, arthralgia, depression, and dyspepsia;
and as adjunct to levodopa therapy include: dyskinesia, accidental injury, weight loss, postural hypotension,
vomiting, anorexia, arthralgia, abdominal pain, nausea, constipation, dry mouth, rash, abnormal dreams,
Please see brief summary of prescribing information on following pages.
Reference: 1. AZILECT Prescribing Information.
Person depicted is a model, not an actual patient.
©2012 Teva Neuroscience, Inc. AZL121013013/122183